Twenty percent of publicly funded cancer clinical trials don't enroll enough patients; KaloBios files for bankruptcy; a new MS campaign in Australia uses bicycles
The NIH plans to fund fewer but more meaningful studies; the FDA asks for more data about AstraZeneca diabetes drug; payers continue to deny coverage for new hep.-C treatments
The legislation would allow drugmakers to share information about their products beyond what is included on the FDA-approved label.
The draft would allow drugmakers to share off-label economic data with payers, a practice that until now has been considered taboo, and require the FDA to assess patient experience data in regulatory decisions, in addition to boosting funding for the NIH.
AbbVie nabs Pharmacyclics for $21 billion, Mallinckrodt makes a Pfizer-Hospira style acquisition, and the National Cancer Institute's director resigns
Lilly delays Phase-III cholesterol drug results; PatientsLikeMe and Walgreens team up for "drug reaction reviews"; Roche skin-cancer drug receives Priority Review.
Obama's precision medicine initiative looks set for bipartisan support, Valeant has offered $296 million to buy Dendreon and researchers say Roche's Tamiflu works.
NIH project for genome sequencing of newborns commences; remote care, next-gen. DNA sequencing top list of 2014 healthcare-market trends; WHO plans evaluation of contagious-disease response.
Canada's National Microbiology Laboratory developed the vaccine, which has been licensed to NewLink Genetics Corp.
A National Institutes of Health-funded study of over 18,000 patients has identified six new genetic risk factors associated with Parkinson's Disease.
HPV testing provides an edge over Pap screenings when it comes to detecting cervical cancer risk.
The National Institutes of Health wants female lab animals to be part of the animal testing mix.
Advocates say the National Institutes of Health is working with 22% less buying power than it had 11 years ago.
The NIH says the information will help researchers find the genetic underpinnings of adult diseases.
Ten pharma companies will share money and biomarker research under an NIH collaboration.
New research finds overlap with some forms of breast, lung, and head & neck cancers, as well as 32 recurring genetic mutations.
People asked, experts answered.
Updates include responsive design and information in Spanish.
The midnight shutdown put 800,000 government employees on leave, including those at the FDA, NIH and CDC.
Sanofi's PCSK9 agent receives high praise from analysts, Consumer Reports analyzes healthcare reform, Congressional committees propose compounding legislation, NIH funds genomic research.
Sanofi has to provide more Aubagio data to the UK's NICE; healthcare reform's sixes and sevens; NIH puts money toward Alzheimer's research
Eli Lilly is the first Big Pharma to team up with the agency in its rare-disease pre-clinical development program.
Two of the most difficult-to-treat hepatitis C patient groups saw high cure rates in an NIH-led study, results released Tuesday show.
Lantus cushions Sanofi's quarterly sales; Allergan holds back on Eylea competitor; FDA limits use of Otsuka drug; Genmab lands Breakthrough label; NIH finds a link among cancers; and Novartis offers lunch with a side of medical information; DOJ appeals Plan-B Ruling.
The Million Hearts initiative just got a Spanish-language rollout, and the culturally sensitive content is starting to gain attention.
- Five things for pharma marketers to know: Wednesday, March 22, 2017
- Drugmakers target severe asthma patients with biologics, but payers raise pricing issue
- Novartis aims to bring first oral asthma drug to market in two decades
- What five different pharma marketing careers look like
- Five things for pharma marketers to know: Monday, March 27, 2017
- 2017 Healthcare Marketers Trend Report: All the data in one place
- Infographic: What's next for the point of care market
- Drugmakers again boost DTC spending, to $5.6 billion in 2016
- Digital IDs become focus as drugmakers seek to track doctors' behavior online
- Some CME experts remain skeptical when it comes to social media